Core Insights - Henry Schein, Inc. (HSIC) has a market capitalization of $8.4 billion and is a prominent global provider of healthcare products and services, primarily catering to dental and medical practitioners [1] - The company has experienced stock underperformance compared to the broader market, with a 7.4% increase in HSIC shares over the past 52 weeks, while the S&P 500 Index rose by 13.2% [2] - HSIC shares surged 10.8% following the announcement of third-quarter earnings that exceeded market expectations, with revenue of $3.34 billion, reflecting a year-over-year increase of 5.2% [4] Financial Performance - The company reported a non-GAAP EPS increase of 13.1% to $1.38, and adjusted EBITDA reached $295 million, up from $268 million in the previous year [5] - Management has raised its full-year 2025 non-GAAP EPS outlook to a range of $4.88–$4.96, anticipating sales growth of 3–4% [5] - Analysts project HSIC's adjusted EPS to grow 3.6% year-over-year to $4.91 for the fiscal year ending in December 2025 [6] Analyst Ratings - Among 15 analysts covering HSIC, the consensus rating is a "Moderate Buy," consisting of five "Strong Buy" ratings, nine "Holds," and one "Strong Sell" [6] - The current analyst configuration is more bullish than three months ago, with four "Strong Buy" ratings on the stock [7] - Leerink Partners analyst Michael Cherny reaffirmed a "Hold" rating on HSIC with a price target of $71 [7]